The 3R principle and the use of non-human primates in the study of neurodegenerative diseases: The case of Parkinson's disease

Neuroscience and Biobehavioral Reviews

Volumn 33, Issue 1, 2009, Pages 33-47

  Vitale, Augusto ^a   Manciocco, Arianna ^a   Alleva, Enrico ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

3R principle; Animal experimentation; Animal welfare; Bioethics; Non human primates; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL MODEL; BIOETHICS; DISEASE COURSE; EXPERIMENTAL ANIMAL WELFARE; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE;

ANIMAL RIGHTS; ANIMAL TESTING ALTERNATIVES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PARKINSON DISEASE; PRIMATES; RESEARCH;

EID: 54049126864     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2008.08.006     Document Type: Review

References (166)

1. Adler C.H. Non motor complications in Parkinson's disease. Mov. Disord. 20 (2005) S23-S29
2. Akazawa T., Takada M., and Nambu A. Activity and distribution patterns of monkey pallidal neurons in response to peripheral nerve stimulation. Neurosci. Lett. 339 (2003) 161-165
3. Amos A. A computational model of information processing in the frontal cortex and basal ganglia. J. Cogn. Neurosci. 12 (2000) 505-519
4. Anderson M.E., Postpna N., and Ruff M. Effects of high-frequency stimulation in the internal globus pallidus on the activity of thalamic neurons in the awake monkey. J. Neurophysiol. 89 (2003) 1150-1160
5. Annett L.E., Dunnett S.B., Martel F.L., Rogers D.C., Ridley R.M., Baker H.F., and Marsden C.D. A functional assessment of embryonic dopaminergic grafts in the marmoset. Prog. Brain Res. 82 (1990) 535-542
6. Annett L.E., Rogers D.C., Hernandez T.D., and Dunnett S.B. Behavioural analysis of unilateral monoamine depletion in marmoset. Brain 115 (1992) 825-856
7. Annett L.E., Torres E.M., Ridlay R.M., Baker H.F., and Dunnett S.B. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions. Exp. Brain Res. 103 (1995) 355-371
8. In: Armstrong S.J., and Botzler R.G. (Eds). The Animal Ethics Reader (2003), Routledge, London
9. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 (2002) 865-868
10. Baker H.F., and Ridley R.M. Use of common marmoset (Callithrix jacchus) in psychopharmacological research. In: Waddington S., and Joseph M.H. (Eds). Working Methods in Multidisciplinary Psychopharmacology (1987), Manchester University Press, Manchester 41-73
11. Baker S.N., Philbin N., Spinks R., Pinches E.M., Wolpert D.M., MacManus D.G., Pauluis Q., and Lemon R.N. Multiple single unit recording in the cortex of monkeys using independently moveable microelectrodes. J. Neurosci. Methods 94 (1999) 5-17
12. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., and Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39 (1986) 7-16
13. Bankiewicz K.S., Hundal R.S., Pivirotto P.J., McLaughlin W.W., Bringas J.R., Yang B.Y., and Emborg M.E. Behavioral and biochemical changes in MPTP-treated monkeys after L-DOPA administration. Exp. Neurol. 145 (1997) S14
14. Barcia C., Sanchez-Bahillo A., Fernandez-Villalba E., Bautista V., Poza Y., Poza M., Fernandez-Barreiro A., Hirsch E.C., and Herrero M. Evidence of active microglia in substantia nigra pars compacta of Parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004) 402-409
15. Baron M.S., Wichmann T., Ma D., and DeLong M.R. Effects of transient focal inactivation of the basal ganglia in Parkinsonian primates. J. Neurosci. 22 (2002) 592-599
16. Bekoff M. Minding Animals: Awareness Emotions and Heart (2002), Oxford University Press, Oxford
17. Bezard E., Imbert C., Deloire X., Bioulac B., and Gross C. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766 (1997) 107-112
18. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A., and Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184 (2003) 285-294
19. Bingaman K.D., and Bakay R.A. The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies. Prog. Brain Res. 127 (2000) 267-297
20. Blanchet P.J., Calon F., Morissette M., Hadj Tahar A., Belanger N., Samadi P., Grondin R., Gregoire L., Meltzer L., Di Paolo T., and Bedard P.J. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat. Disord. 10 (2004) 297-304
21. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov. Disord. 18 (2003) 357-363
22. Brown P., and Marsden C.D. What do the basal ganglia do?. Lancet 351 (1998) 1801-1804
23. Brownell A.L., Canales K., Chen Y.I., Jenkins B.G., Owen C., Livni E., Yu M., Cicchetti F., Sanchez-Pernaute R., and Isacson O. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage 20 (2003) 1064-1075
24. Buchanan-Smith H.M., Rennie A.E., Vitale A., Pollo S., Prescott M.J., and Morton D.B. Harmonising the definition of refinement. Anim. Welf. 14 (2005) 379-384
25. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridin. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 4546-4550
26. In: Cavalieri P., and Singer P. (Eds). The Great Ape project (1993), Fourth Estate, London
27. Chassain C., Eschalier A., and Durif F. Assessment of motor behavior using a video system and a clinical rating scale in Parkinsonian monkeys lesioned by MPTP. J. Neurosci. Methods 111 (2001) 9-16
28. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Pert A., and Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur. J. Pharmacol. 10 (1984) 189-194
29. Collier T.J., Dung Ling Z., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek Jr. J.R., and Kordower J.H. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced Parkinsonism. Exp. Neurol. 191 (2005) S60-S67
30. Crossman A.R., and Sambrook M.A. Experimental torticollis in the monkey produced by unilateral 6-hydroxydopamine brain lesions. Brain Res. 149 (1978) 498-502
31. Crossman A.R., Mitchell I.J., and Sambrook M.A. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism in the macaque monkey. Neuropharmacology 24 (1985) 587-591
32. Costa S., Iravani M.M., Pearce R.K., and Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412 (2001) 45-50
33. Council of Europe, 1986. 86/608EEC. http://europa.eu.int/comm/food/fs/aw/aw_legislation/scientific/86-609-eec_en.pdf.
34. de Boo M.J., Rennie A.E., Buchanan-Smith H.M., and Hendriksen C.F.M. The interplay between replacement, reduction and refinement: considerations where the three Rs interact. Anim. Welf. 14 (2005) 327-332
35. De Cock Buning T. What apes teach us about ethics. In: Corbey R., and Theunissen B. (Eds). Ape, Man Apeman: Changing Views Since 1600 vol. 385 (1995), Leiden University, Leiden 394
36. De Grazia D. Equal consideration and unequal moral status. In: Armstrong S.J., and Botzler R.G. (Eds). The Animal Ethics Reader vol. 54 (2003), Routledge, London 61
37. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13 (1990) 281-285
38. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
39. Driver S. The economic use of laboratory animals?. Lab Anim. Eur. 8 (2008) 3
40. Drouot X., Oshino S., Jarraya B., Besret L., Kishima H., Remy P., Dauguet J., Lefaucheur J.P., Dolle F., Conde F., Bottlaender M., Peschanski M., Keravel Y., Hantraye P., and Palfi S. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron 44 (2004) 769-778
41. Duda J.E., Lee V.M., and Trojanowski J.Q. Neuropathology of synuclein aggregates. J. Neurosci. Res. 61 (2000) 121-127
42. Egelman D.M., Person C., and Montague P.R. A computational role for dopamine delivery in human decision-making. J. Cogn. Neurosci. 10 (1998) 623-630
43. Eidelberg E. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydrophyne model of Parkinsonism in monkeys. Neuroscience 18 (1986) 817-822
44. Elsworth J.D., Deutch A.Y., Redmond D.E., Sladek J.R., and Roth R.H. MPTP-induced Parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res. 513 (1990) 320-324
45. Elsworth J.D., Taylor J.R., Sladek J.R., Collier T.J., Redmond D.E., and Roth T.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in Old-World primates one year after MPTP treatment. Neuroscience 95 (2000) 399-408
46. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139 (2004) 121-143
47. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., Holden J.E., and Kordower J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401 (1998) 253-265
48. Emborg-Knott M.E., and Domino E.F. MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Exp. Neurol. 152 (1998) 214-220
49. Escola L., Michelet T., Macia F., Guehl D., Bioulac B., and Burbaud P. Disruption of information processing in the supplementary motor area of the MPTP-treated monkey: a clue to the pathophysiology of akinesia?. Brain 126 (2003) 95-114
50. Eslamboli A. Marmoset monkey models of Parkinson's disease: which model, when and why?. Rev. Neurosci. 16 (2005) 303-310
51. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Annett L., and Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25 (2005) 769-777
52. Flecknell P., and Waterman-Pearson A. Pain Management in Animals (2001), WB Saunders, London
53. Forno L.S., DeLanney L.E., Irwin I., and Langston J.W. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease neuropathologic considerations. Adv. Neurol. 60 (1993) 600-608
54. Forno L.S., DeLanney L.E., Irwin I., and Langston J.W. Ultrastructure of eosinophilic inclusion bodies in the amygdala-parahippocampal region of aged squirrel monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci. Lett. 184 (1995) 44-47
55. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
56. Freed C.R., Richards J.B., Hutt C., and Sabol K.E. Relief of Parkinson's syndrome in monkeys by brain grafts of fetal substantia nigra. Clin. Res. 36 (1988) 548A
57. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
58. Gerlach M., and Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural. Transm. 103 (1996) 987-1041
59. Gnanalingham K.K., Hunter A.J., Jenner P., and Marsden C.D. Selective dopamine antagonistpretreatment on the antiparkinsonian effects of benzazepine D1dopamine agonists in rodent and primate models of Parkinson's disease. Psychopharmacology 117 (1995) 403-412
60. Goldstein M., Anagnoste B., Battista A.F., Nakatani S., and Ogawa M. Biochemical aspects of experimentally induced parkinsonism vol. 50 (1972), Research Publications, Association for Research in Nervous and Mental Disease pp. 447-437
61. Goldstein M., Battista A.F., Lieberman A., Lew J.Y., and Hata F. The use of animal model for parkinsonism and its extension to human parkinsonism. In: Hanin I., and Usdin E. (Eds). Animal Models in Psychiatry and Neurology (1977), Pergamon Press, Oxford 331-338
62. Goldstein D.S., Li S.T., Holmes C., and Bankiewicz K. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J. Pharmacol. Exp. Ther. 306 (2003) 855-860
63. Gonzalez C.A., Coe C.L., and Levine S. Cortisol responses under different housing conditions in female squirrel monkeys. Psychoneuroendocrinology 7 (1982) 209-216
64. Gray C.M., Goodell B., and Lear A. Multichannel micromanipulator and chamber system for recording multineuronal activity in alert, non-human primates. J. Neurophysiol. 98 (2007) 527-536
65. Greeenberg M.J., and Price D.A. Invertebrate neuropeptides: native and naturalized. Ann. Rev. Physiol. 45 (1983) 271-288
66. Guridi J., Herrero M.T., Luquin M.R., Guillen J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., and Obeso J.A. Subthalamotomy in parkinsonian monkeys behavioural and biochemical analysis. Brain 119 (1996) 1717-1727
67. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., and Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48 (2005) 503-516
68. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J.C., and Maziere M. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53 (1993) 169-178
69. Hashimoto T., Elder C.M., Okum M.S., Patrick S.K., and Vitek J.L. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurone. J. Neurosci. 23 (2003) 1916-1923
70. In: Hendriksen C.F.M., and Morton D.B. (Eds). Humane Endpoints in Animal Experiments for Biomedical Research (1999), Royal Society of Midecine Press, London
71. Hennessy M.B. Presence of companion moderates arousal of monkeys with restricted social experience. Physiol. Behav. 33 (1984) 693-698
72. Herrero M.T., Hirsch E.C., Kastner A., Ruberg M., Luquin M.R., Laguna J., Javoy-Agid F., Obeso J.A., and Agid Y. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?. Neuroscience 56 (1993) 499-511
73. Hill M.P., Ravenscroft P., Bezard E., Crossman A.R., Brotchie J.M., Michel A., Grimee R., and Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J. Pharmacol. Exp. Ther. 310 (2004) 386-394
74. Ho A., and Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J. Neurosci. 18 (1998) 5614-5629
75. Home Office. Statistics of Scientific Procedures on Living Animals in Great Britain (2005), C.M. p. 6877
76. Honess P.E., Marin C., Brown A.P., and Wolfensohn S.E. Assessment of stress in non-human primates: application of the neutrophil activation test. Anim. Welf. 14 (2005) 291-295
77. Imbert C., Bezard E., Guitraud S., Boraud T., and Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J. Neurosci. Methods 96 (2000) 71-76
78. Israel Z., and Bergman H. Pathophysiology of the basal ganglia and movement disorders: from animal models to human clinical applications. Neurosci. Biobehav. Rev. 32 (2008) 367-377
79. Jackson M.J. Environmental enrichment and husbandry of the MPTP-treated common marmoset. Anim. Technol. 52 (2001) 21-28
80. Jenkinson N., Nandi D., Miall R.C., Stein J.F., and Aziz T.Z. Peduncolopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 15 (2004) 2621-2624
81. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61 (2003) S4-S11
82. Jenner P., and Marsden C.D. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J. Neural. Transm. 20 (1984) 11-39
83. Jenner P., Rupniak N.M.J., Rose S., Kelly E., Kilpatrick G., Lees A., and Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50 (1984) 85-90
84. Jenner P., Taquet H., Mauborgne A., Benoliel J.T., Cesselin F., Rose S., Javoy-Agid F., Agid Y., and Marsden C.D. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset. J. Neurochem. 47 (1986) 1548-1551
85. Joyce J.N., Presgraves S., Renish L., Borwege S., Osredkar T., Hagner D., Replogle M., PazSoldan M., and Millan M.J. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp. Neurol. 184 (2003) 393-407
86. King J.E., and Landau V.I. Can chimpanzee (Pan troglodytes) happiness be estimated by human raters?. J. Res. Pers. 1 (2003) 1-15
87. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., and Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2884-2889
88. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease, pathophysiologic and clinical implications. N. Engl. J. Med. 318 (1988) 876-880
89. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
90. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Clin. Neurosci. Neuropathol. 11 (2000) 211-213
91. Kringelbach M.L., Jenkinson N., Owen S.L., and Aziz T.Z. Translational principles of deep brain stimulation. Nat. Rev. Neurosci. 8 (2007) 623-635
92. Kurlan R., Kim M.H., and Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys:assessment with a new rating scale for monkey parkinsonism. Mov. Disord. 6 (1991) 111-118
93. Langford D.J., Crager S.E., Shehzad Z., Smith S.B., Sotocinal S.G., Levenstadt J.S., Chanda M.L., Levitin D.J., and Mogil J.S. Social modulation of pain as evidence for empathy in mice. Science 312 (2006) 1967-1970
94. Langston J.W., Quik M., Petzinger G., Jakowec M., and Di Monte D.A. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann. Neurol. 47 (2000) S79-S89
95. Lee D., Port N.L., Kruse W., and Georgopoulos A.P. Variability and correlated noise in the discharge of neurons in motor and parietal areas of the primate cortex. J. Neurosci. 18 (1998) 1161-1170
96. Leist M., Single B., Naumann H., Fava E., Simon B., Kuhnle S., and Nicotera P. Inibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp. Cell. Res. 249 (1999) 396-403
97. Littin K., Acevedo A., Browne W., Edgar J., Mendl M., Owen D., Sherwin C., Wurbel H., and Nicol C. Towards humane end points: behavioural changes precede clinical signs of disease in a Huntington's disease model. Proc. Biol. Sci. 275 (2008) 1865-1874
98. Maazloom S., and Smith Y. Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Comp. Neurol. 495 (2006) 453-469
99. Macht M., Schwarz R., and Ellgring H. Patterns of psychological problems in Parkinson's disease. Acta. Neurol. Scand. 111 (2005) 95-101
100. Maratos E.C., Jackson M.J., Pearce R.K., Cannizzaro C., and Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol. 179 (2003) 90-102
101. Maries E., Dass B., Collier T.J., Kordower J.H., and Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4 (2003) 727-738
102. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., and Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
103. Marras C., and Tanner C.M. Epidemiology of Parkinson disease. In: Watts R.L., and Koller W.C. (Eds). Movement Disorders: Neurologic Principles and Practice vol. 117 (2004), McGraw-Hill, New York 195
104. Mason J. Restraining chair for the experimental study of primates. J. Appl. Physiol. 12 (1958) 130-133
105. Mason J.W., Mougey E.H., and Kenion C.C. Urinary epinephrine and norepinephrine responses to chair restraint in the monkey. Physiol. Behav. 10 (1973) 801-803
106. McNamara Jr. J.A. Restraint of monkeys for craniofacial research. J. Dent. Res. 52 (1973) 183
107. Millan M.J., Di Cara B., Hill M., Jackson M., Joyce J.N., Brotchie J., McGuire S., Crossman A., Smith L., Jenner P., Gobert A., Peglion J.L., and Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodents, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J. Pharmacol. Exp. Ther. 309 (2004) 921-935
108. Miller W.C., and DeLong M.R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter M.B., and Jayaraman A. (Eds). The Basal Ganglia II vol. 415 (1987), Plenum Press, New York 427
109. Mitchell I.J., Cross A.J., Sambrook M.A., and Crossman A.R. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61 (1985) 195-200
110. Mitchell I.J., Hughes N., Carroll C.B., and Brotchie J.M. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol. 6 (1995) 492-507
111. In: Moberg G.P., and Mench J.A. (Eds). The Biology of Animal Stress. Basic Principles and Implications for Animal Welfare (2000), CABI Publishing, Wallingford, UK
112. Moerlein S.M., Stocklin G., Pawlik G., Wienhard K., and Heiss W.D. Regional cerebral pharmacokinetics of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as examined by positron emission tomography in a baboon is altered by tranylcypromine. Neurosci. Lett. 66 (1986) 205-209
113. Monchi O., Taylor G.J., and Dagher A. A neural model of working memory processes in normal subjects Parkinson's disease and schizophrenia for fMRI design and prediction. Neural Netw. 13 (2000) 953-973
114. Montague P.R., Hyman S.E., and Cohen J.D. Computational roles fro dopamine in behavioural control. Nature 431 (2004) 760-767
115. Moody D.B., Stebbins W.C., and Miller J.M. Behav. Res. Meth. Instrum. Comput. 2 (1970) 180-182
116. Morrow-Tesch J.L., McGlone J.J., and Norman R.L. Consequences of restraint stress on natural killer cell activity, behavior, and hormone levels in rhesus macaques (Macaca mulatta). Psychoneuroendocrinology 18 (1993) 383-395
117. Nakamura R.K., Coates R., Crawford H., and Friedman D. A flexible restraint chair for the cynomolgus monkey (Macaca fascicularis). Am. J. Primatol. 11 (1982) 178-185
118. National Institutes of Health. Public Health Service Policy on Humane care and Use of Laboratory Animals (2002), Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD. http://grants.nih.gov/grants/olaw/references/phspol.htm
119. Nichols A.M., Ruffner T.W., Sommer M.A., and Wurtz R.H. A scrwew microdrive for adjustable chronic unit recording in monkeys. J. Neurosci. Methods 81 (1998) 185-188
120. Nini A., and Feingold A. Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J. Neurophysiol. 74 (1995) 1800-1805
121. Norman R.L., and Smith C.J. Restraint inhibits luteinizing hormone and testosterone secretion in intact male rhesus macaques: effects of concurrent nalaxone administration. Neuroendocrinology 55 (1992) 405-415
122. Nunez J., Maldonado H., Miralto A., and Balderrama N. The stingine response of the honeybee: effects of morphine, naloxone and some opioid peptides. Pharmacol. Biochem. Behav. 19 (1983) 921-924
123. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7
124. Oiwa Y., Eberling J.L., Nagy D., Pivirotto P., Emborg M.E., and Bankiewicz K.S. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front. Biosci. 8 (2003) 155-166
125. O'Reilly F., Finnan F., Allwright S., Smith G.D., and Ben-Shlomo Y. The effects of caring for a spouse with Parkinson's disease on social, psychological and physical well-being. Br. J. Gen. Pract. 46 (1996) 507-512
126. Pereira E.A., and Aziz T.Z. Parkinson's disease and primate research: past, present and future. Postgrad. Med. J. 82 (2008) 293-299
127. Perez-Otano I., Oset C., Luquin M.R., Herrero M.T., Obeso J.A., and Del Rio J. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci. Lett. 175 (1994) 121-125
128. Pessiglione M., Guehl D., Agid Y., Hirsch E.C., Feger J., and Tremblay L. Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. Brain 126 (2003) 1392-1408
129. Petzinger G.M., and Jakowec M.W. Animal models of basal ganglia injury and degeneration and their application to Parkinson's disease research. Combined Section Meeting, Neurology Section. Opryland, TN (2004) 1-64
130. Petzinger G.M., and Langston J.W. The MPTP-lesioned non-human primate: a model for Parkinson's disease. In: Marwah J., and Teitelbaum H. (Eds). Advances in Neurodegenerative Disease. Volume I: Parkinson's Disease (1998), Prominent Press, Scottsdale, AZ 113-148
131. Pollo S., Vitale A., Gayle V., and Zucco F. The "3Rs" Model and the concept of alternatives in animal research: a questionnaire survey. Lab. Anim. Eur. 33 (2004) 47-53
132. Prescott M.J., and Buchanan-Smith H.M. Training nonhuman primates using positive reinforcement techniques. J. Appl. Anim. Welf. Sci. 6 (2003) 157-161
133. Prescott M.J., and Buchanan-Smith H.M. Training laboratory-housed non-human primates, part 1: a UK survey. Anim. Welf. 16 (2007) 21-36
134. In: Pryce C., Scott L., and Schnell C. (Eds). Marmosets and Tamarins in Biological Research (1997), DSSD Imagery, Salisbury
135. Przedborski S., and Vila M. The last decade in Parkinson's disease research. Adv. Neurol. 86 (2001) 177-186
136. Puopolo M., Santucci D., Chiarotti F., and Alleva E. Behavioural effects of endocrine disrupting chemicals on laboratory rodents: statistical methodologies and an application concernine development PCB exposure. Chemosphere 39 (1999) 1259-1271
137. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 51 (1998) S25-S29
138. Raz A., Frechter-Mazar V., Feingold A., Abeles M., Vaadia E., and Bergman H. Activity of pallidal and striatal tonically active neurons is correlated in MPTP treated monkeys but not in normal monkeys. J. Neurosci. 21 (2001) 1-5
139. Reinhardt V. Impact of venipuncture on physiological research conducted in conscious macaques. J. Exp. Anim. Sci. 34 (1991) 212-217
140. Reinhardt V., Houser D., Cowley D., Eisele S., and Vertein R. Alternatives to single caging of rhesus monkeys (Macaca mulatta) used in research. Zeitschrift fuer Versuchstierkunde 32 (1989) 275-279
141. Rennie A.E., and Buchanan-Smith H.M. Refinement of the use of non-human primates in scientific research. Part I. The influence of humans. Animal 15 (2006) 203-213
142. Rennie A.E., and Buchanan-Smith H.M. Refinement of the use of non-human primates in scientific research. Part II. Housing, husbandry and acquisition. Anim. Welf. 15 (2006) 215-238
143. Rennie A.E., and Buchanan-Smith H.M. Refinement of the use of non-human primates in scientific research. Part III. Refinement of procedures. Anim. Welf. 15 (2006) 239-261
144. Rivlin-Etzion M., Marmor O., Saban G., Rosin B., Haber S., Vaadia E., Prut Y., and Bergman H. Low-pass filter properties of basal ganglia-cortical-muscle loops in the normal and MPTP primate model of Parkinsonism. J. Neurosci. 28 (2008) 633-649
145. Russell W.M.S., and Burch R.L. The Principles of Humane Experimental Technique (1959), Universities Federation for Animal Welfare Wheathampstead, England (reprinted in 1992)
146. Sambrook M.A., Crossman A.R., and Slater P. Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway. Exp. Neurol. 63 (1979) 583-593
147. Scarmeas N., Hadjigeorgiou G.M., Papadimitriou A., Dubois B., Sarazin M., Brandt J., Albert M., Marder K., Bell K., Honig L.S., Wegesin D., and Stern Y. Motor signs during the course of Alzheimer disease. Neurology 63 (2004) 975-982
148. Shapiro S.J., Bloomsmith M.A., and Laule G.E. Positive reinforcement training as a technique to alter nonhuman primate behavior: quantitative assessments of effectiveness. J. Appl. Anim. Welf. Sci. 6 (2003) 157-187
149. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
150. Shulman J.M., Shulman L.M., Weiner W.J., and Feany M.B. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr. Opin. Neurol. 16 (2003) 443-449
151. Singer P. Animal Liberation: A New Ethics for Our Treatments of Animals (1983), Thorsons Publishing, London
152. Smith R.D., Zhang Z., Kurlan R., McDermott M., and Gash D.M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52 (1993) 7-16
153. Still A.W. On the number of subjects used in animal behaviour experiments. Anim. Behav. 30 (1982) 873-880
154. Suri R.E., and Schultz W. Neural network model with dopamine-like reinforcement signal that learns a spatial delayed response task. Neuroscience 91 (1999) 871-890
155. Tande D., Hoglinger G., Debeir T., Freundlieb N., Hirsch E.C., and Francois C. New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 129 (2006) 1194-1200
156. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., and Redmond Jr. D.E. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 81 (1997) 745-755
157. Taylor N.R., and Taylor J.G. Modelling the frontal lobes in health and disease. Proceedings of the International Conference on Artificial Neural Network, vol. 1 (1999) 401-406
158. Trajstmann A.C. Engineering to reduce animal numbers. In: Balls M., van Zeller A.M., and Halder M. (Eds). Progress in the Reduction and Replacement of Animal Experimentation (2000), Elsevier, Amsterdam 726-736
159. Vitale A., and Alleva E. Ethological and welfare considerations in the study of aggression in rodents and nonhuman primates. In: Haug M., and Whalen R.E. (Eds). Animal Models of Human Emotion and Cognition (1999), American Phychological Association, Washington 283-295
160. Vu T.Q., Ling Z.D., Ma S.Y., Robie H.C., Tong C.W., Chen E.Y., Lipton J.W., and Carvey P.M. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J. Neural Transm. 107 (2000) 159-176
161. Wichmann T., and DeLong M.R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 91 (2003) 9-18
162. Wichmann T., Kliem M.A., and DeLong M.R. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp. Neurol. 167 (2001) 410-424
163. Willis G.L., and Robertson A.D. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol. Biochem. Behav. 79 (2004) 413-429
164. Wooten G.F., Curie I.J., Bovbjerg V.E., Lee J.K., and Patrie J. Are men at greater risk for Parkinonson's disease than women?. J. Neurol. Neurosurg. Psychiatry 75 (2004) 637-639
165. Zamir N., Skofitsch G., Bannon M.J., Helke C.J., Kopin I.J., and Jacobowitz D.M. Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia. Brain Res. 322 (1984) 356-360
166. Ziv I., Melamed F., Nardi N., Luria D., Achiron A., Offen D., and Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons-a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170 (1994) 136-140